In January 2026, the U.S. FDA publicly reinforced a flexible, risk-based approach to CMC requirements for cell and gene therapies. The agency emphasized that minor manufacturing changes can be supported by focused, science-driven comparability data rather than disproportionate revalidation efforts: See here!
This regulatory approach strongly aligns with c-LEcta’s Change Guidance Documents, which help manufacturers manage raw and ancillary material changes in approved biopharmaceutical manufacturing processes.
c-LEcta provides customers with clear, regulatory-aligned support for an efficient and confident implementation of changes covering
Defined qualification elements
Structured Risk assessments
Targeted Comparability activities.
Together, FDA’s clarified flexibility and c-LEcta’s practical change guidance underscore a shared principle: manufacturing change is a normal, expected part of a product’s lifecycle - and, with the right scientific framework and regulatory support, it can be executed efficiently, safely and without unnecessary delay.
Whether you are considerung the replacement of a trypsin-like enzyme or an endonuclease in your approved manufacturing process - c-LEcta’s Change Guidance Documents help you navigate raw and ancillary material changes with confidence, using a regulatory aligned framework.